BG00011

DRUG2 trials

Sponsors

Biogen

Conditions

Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)

Phase 2

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT01371305

BiogenIdiopathic Pulmonary Fibrosis (IPF)

Start: 2012-07-16End: 2017-03-31Updated: 2020-02-28

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

TerminatedNCT03573505

BiogenIdiopathic Pulmonary Fibrosis

Start: 2018-09-24End: 2019-11-14Updated: 2020-12-11

Related Papers

Proteome-wide Mendelian Randomisation Analyses to Identify Potential Therapeutic Targets for Lung Function and Respiratory Disease

American Journal of Respiratory and Critical Care Medicine2025-05-01

An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis

ERJ Open Research2024-01-013 citations

A Phase IIb Randomized Clinical Study of an Anti-α <sub>v</sub> β <sub>6</sub> Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

American Journal of Respiratory and Critical Care Medicine2022-06-3090 citations